SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GEB - Genetronics Biomedical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zakaran who wrote (19)8/2/2000 2:52:17 AM
From: Alfred W. Post  Read Replies (1) of 31
 
Here is the answer of the company;
"Ethicon Endo-Surgery exercised their right to terminate the agreements without cause. They did not elaborate as to why they ended the agreements.

Genetronics has approval to market and sell the product in Europe. We have also released the data about our Phase II trial results in May of 1999 where 64% of the tumors we treated achieved a clinical response (50% or greater tumor shrinkage). We feel those results are encouraging and we look forward to entering into a pivotal Phase III trial in the future."

As an unhapy investor I guess rhe only thing one can now do is hopeing that things are not as bad as they sound. FRED
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News